IL16 and psoriasis: In the multivariable MR analysis, the pathogenic effects of genetically-predicted psoriasis on AMI risk attenuated the OR (OR = 1.00080; 95% CI: 1.00014–1.00145; P = .016773) in inverse variance weighting univariable analysis to the OR of 1.00060 (95% CI: 1.00008–1.00112; P = .024380) after adjusting for genetically-predicted ESAM; to the OR of 1.0067 (95% CI: 1.00010–1.00124; P = .020854) after adjusting for genetically-predicted IL-16; and to the OR of 1.00058 (95% CI: 1.00009–1.00107; P = .019478) after adjusting for both genetically-predicted ESAM and IL-16 (Fig. 3).